Complejo Hospitalario de Jaén

The medical center is at the forefront of research in allergy and immunotherapy, focusing on innovative treatments for pollen allergies. The ongoing studies aim to enhance the efficacy and safety of subcutaneous cluster-immunotherapy for patients with Olea europaea pollen allergy.

• Subcutaneous Cluster-Immunotherapy
• Olea Europaea Pollen Allergy
• Combined Symptom and Medication Score (CSMS)

By exploring the optimal dosing strategies, the center contributes significantly to improving the benefit-risk balance in allergy treatments, offering hope for those suffering from moderate-to-severe allergic rhinitis and rhinoconjunctivitis.

Specializing in oncology, the center is pioneering a chemotherapy-free approach for HER2-positive early breast cancer. The research focuses on a pCR-guided strategy using subcutaneous trastuzumabpertuzumab and T-DM1 to improve patient outcomes.

• HER2-Positive Early Breast Cancer
• pCR-Guided Strategy
• Subcutaneous Trastuzumabpertuzumab and T-DM1

By assessing the 3-year recurrence-free interval and monitoring global health status, the center is advancing the understanding of breast cancer treatment, aiming to reduce recurrence and improve quality of life for patients.